CANCER BUZZ PODCAST

This rule-based informatics solution pulls from the electronic health record to automate the election of an appropriate biosimilar therapy based on the patient’s insurance, hospital formulary preferences, streamlining prior authorization and approvals.

In this episode, CANCER BUZZ speaks with Niharika Dixit, MD, medical oncologist at Zuckerberg San Francisco General Hospital and professor of medicine at UCSF Helen Diller Family Comprehensive Cancer Center.

Immunotherapy is redefining survivorship to include an increasing population of patients who live with cancer and navigate toxicities that differ from those that accompany traditional treatments.

Germline and somatic testing for prostate cancer can improve outcomes and promote early detection and prevention, yet many patients are not aware of testing and the impact it can have on treatment options.

This discussion elucidates an array of patient-centered approaches, touches on social determinants of health, and highlights collaborative measures to support care coordination in the management of anemia in patients with high-risk MDS and AML

The primary goals of the initiative were to transform patient experience and improve timeliness to care for every newly diagnosed patient.

Improving timely identification and referral of patients who may be eligible for chimeric antigen receptor (CAR) T-cell therapy is critical for improving outcomes for patients with hematologic malignancies.

4R Oncology® model in breast and lung cancer clinics has improved patients’ involvement in organizing their care, enabled the development of high-functioning multidisciplinary care teams, and helped optimize the timing and coordination of sequence of care

In this episode, Alessandro Villa, DDS, PhD, MPH, chief of Oral Medicine, Oral Oncology, and Dentistry at Baptist Health South Florida’s Miami Cancer Institute, emphasizes the proactive role dentists can play in early identification of cancer

CANCER BUZZ speaks with Aaron Cumpston, PharmD, and Christine Barrett, PharmD, BCOP, who discuss the challenges of care coordination and therapy and share operational best practices for the delivery of bispecific antibodies in the community setting.

As the need for access to guideline-concordant biomarker testing for underserved populations continues to grow.

In this episode, CANCER BUZZ speaks with Linda Hayward, patient financial advocate at the University of Maryland, Kaufman Cancer Center at Upper Chesapeake Health

The ACCC Oncology Reimbursement Meetings (ORMs) help all members of the multidisciplinary cancer care team navigate the annual changes in oncology reimbursement and regulations

Maintenance therapy for patients with acute myeloid leukemia, particularly those who are ineligible for transplant, can be critical to treatment outcomes and quality of life for patients.

CANCER BUZZ interviews outgoing President, Lekan Ajayi, and incoming President, Nadine Barrett, about their respective ACCC President’s Themes, the programs and resources ACCC developed in the past year, the Association’s 50th Anniversary, and more.

From the ACCC 50th Annual Meeting and Cancer Center Business Summit (AMCCBS), Krista Nelson, ACCC past president, about the new Institute for Comprehensive Cancer Care Services and resources for cancer centers to implement these services.

Dr. Sarah Hudson-DiSalle, member of the Reimbursement and Economics Subcommittee of ACCC’s Governmental Affairs Committee, about this week’s Hill Day, when members of ACCC met with Capitol Hill offices to advocate on behalf of patients.

Live this week from the ACCC 50th Annual Meeting and Cancer Center Business Summit (AMCCBS), CANCER BUZZ features an update from the White House on the Biden Cancer Moonshot program.

Live this week from the ACCC 50th Annual Meeting and Cancer Center Business Summit (AMCCBS), CANCER BUZZ interviews Dr. Mandi Pratt-Chapman about new patient navigation payments.

Live this week from the ACCC 50th Annual Meeting and Cancer Center Business Summit (AMCCBS), CANCER BUZZ interviews Wendi Waugh, ACCC financial navigation committee member, about resources for financial advocacy.

Recent advancements in treatment and a multimodal approach to care are improving outcomes for patients with head and neck cancer, however access to therapies and unique patient challenges and other psychosocial factors can reduce patient quality of life.

Founded in 2019, this inclusive lab is comprised of 42 members ranging from undergraduates to faculty from 12 different countries, most of whom self-identify as women and/or individuals who are under-represented in medicine.

Hereditary breast cancer is a significant concern, with BRCA1 and BRCA2 mutations accounting for many inherited breast cancer cases.

In this podcast, Mila Felder, MD, FACEP, teases her keynote at the ACCC 50th Annual Meeting & Cancer Center Business Summit, why it’s important to attend this session in person, and what she’s looking forward to most at the meeting.